soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 πΈπͺ #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Oral Semaglutide's Impact on Cardiovascular
Pay in 4 interest-free payments of $5.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 12 - Sep 17











:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)















